Bronchogen Peptide

Bronchial bioregulatory tetrapeptide normalizing respiratory epithelium function. Research demonstrates restored mucociliary clearance, reduced inflammatory infiltration, and normalized goblet cell secretion in bronchial tissue models.

Bronchogen (Ala-Glu-Asp-Leu, AEDL) is a short bioregulatory peptide belonging to the Khavinson family of tissue-specific peptide bioregulators. Like other members of this class (Vilon, Epitalon, Thymogen), Bronchogen exerts its effects through gene-expression modulation rather than classical receptor-ligand signaling. Research suggests that the tetrapeptide penetrates cellular and nuclear membranes, where it interacts with specific DNA sequences in promoter regions of genes governing bronchial epithelial differentiation, mucin synthesis, and antioxidant defense.

Epigenetic and Transcriptional Modulation

In vitro experiments on cultured bronchial epithelial cells indicate that AEDL binds preferentially to AT-rich regions of double-stranded DNA. This binding has been associated with site-specific demethylation of CpG islands in the promoters of MUC5AC, SCGB1A1 (Clara cell secretory protein), and NKX2-1 (TTF-1) — master regulators of bronchial epithelial identity. Through this mechanism, Bronchogen is hypothesized to restore the differentiated phenotype of aged or damaged bronchial cells.

Modulation of Cell Renewal Pathways

Studies in organotypic bronchial cultures have shown that AEDL increases proliferative activity of basal epithelial cells (measured by Ki-67 and PCNA expression) while simultaneously promoting their differentiation into ciliated and secretory phenotypes. This dual effect — stimulating proliferation in stem-like compartments while driving terminal differentiation in suprabasal layers — is characteristic of the Khavinson bioregulator class.

Anti-Inflammatory and Antioxidant Effects

Bronchogen has been associated with downregulation of NF-κB-dependent inflammatory cytokines (TNF-α, IL-6, IL-8) and upregulation of antioxidant enzymes including superoxide dismutase (SOD2) and glutathione peroxidase (GPX1) in bronchial tissue models. This shifts the local redox balance toward a state more resistant to oxidative damage from cigarette smoke, pollutants, and chronic inflammation — environmental stressors central to the pathophysiology of COPD models.

Comparison to Related Bioregulators

Unlike Thymalin or Thymogen (Glu-Trp), which act primarily on T-cell maturation, Bronchogen demonstrates organ tropism for bronchial and alveolar tissues. Its mechanism parallels that of Chonluten (Glu-Asp-Gly), another respiratory-tropic peptide, but Bronchogen appears to act preferentially on the conducting airway epithelium while Chonluten targets alveolar pneumocytes. This tissue specificity is thought to arise from differential affinity for promoter regions of lineage-specific transcription factors.

Downstream Effects

Collectively, these molecular events translate into preclinical observations of: improved mucociliary clearance, normalized mucus rheology, reduced goblet cell hyperplasia in inflammation models, restored ciliary beat frequency, and decreased apoptosis of bronchial epithelial cells under oxidative challenge. Research in aged rodent models has documented partial restoration of bronchial morphometric parameters toward those of younger animals, supporting the hypothesis that Bronchogen acts as a geroprotector for respiratory tissues.

Bronchogen is one of the smallest and simplest peptides in the Khavinson bioregulator family, consisting of just four amino acids with a relatively low molecular weight of 460.48 g/mol. This small size confers several practical advantages: excellent water solubility, stability during lyophilization, minimal aggregation tendency, and the ability to penetrate cellular and nuclear membranes without requiring specialized transport systems. The peptide contains two acidic residues (glutamic and aspartic acid), giving it a net negative charge at physiological pH, which is thought to facilitate its interaction with the positively charged histone proteins and AT-rich DNA regions implicated in its mechanism of action. The C-terminal leucine residue contributes hydrophobic character that may aid membrane translocation. Unlike larger peptides, AEDL does not contain cysteine residues and therefore is not subject to disulfide-bond-related stability issues. It also lacks methionine, avoiding the oxidation concerns common to peptides like Semax or Selank. These properties make Bronchogen one of the more chemically robust peptides for laboratory handling and storage.

Bronchogen is supplied as a sterile lyophilized powder and requires reconstitution in a suitable aqueous solvent prior to in vitro use. As a small tetrapeptide (460.48 g/mol) lacking disulfide bridges or oxidation-sensitive residues such as methionine or cysteine, Bronchogen is relatively robust compared to larger peptides, but standard sterile peptide handling practice should still be followed in all research contexts.

Recommended Reconstitution Protocol:

1. Allow the sealed vial to equilibrate to room temperature for 20-30 minutes to prevent condensation forming on the lyophilizate when opened.
2. Briefly centrifuge the vial (if possible) to ensure all powder is collected at the bottom.
3. Using a sterile syringe, slowly inject bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water for injection down the inner wall of the vial. Do not inject directly onto the powder.
4. Swirl the vial gently to dissolve. Do not shake or vortex aggressively, as mechanical agitation can cause foaming and may damage peptide bonds.
5. Allow the vial to stand for 1-2 minutes until the solution is fully clear and homogeneous.
6. Inspect visually: the reconstituted solution should be clear and colourless with no particulates.

Concentration Calculation Example: A 20 mg vial reconstituted with 2 mL of solvent yields a concentration of 10 mg/mL (10,000 ng/μL). For a working concentration of 100 ng/mL, dilute 1 μL of stock into 100 mL of culture medium, or perform serial dilutions for finer control.

Compound-Specific Notes:

• Bronchogen is highly water-soluble due to its small size and the presence of charged residues (glutamic acid, aspartic acid). Reconstitution at concentrations up to 20 mg/mL is typically achievable.
• The peptide contains no cysteine, so no inert atmosphere is required for handling. However, prolonged exposure to air and moisture should be avoided.
• Use only sterile glassware or pyrogen-free plastic consumables. Avoid contact with metal surfaces beyond standard sterile syringes.
• All handling should occur in a laminar flow hood or sterile bench when intended for cell culture use.

Once reconstituted, Bronchogen should be aliquoted into single-use volumes to minimise repeated freeze-thaw cycles, which can degrade peptide integrity over time.

Proper storage is essential to preserve the structural integrity and bioregulatory activity of Bronchogen (Ala-Glu-Asp-Leu) throughout its research use. As a small linear tetrapeptide, Bronchogen is generally more stable than larger or modified peptides, but it remains susceptible to hydrolysis, microbial contamination, and gradual degradation if not stored correctly.

Lyophilized Powder Storage:

• Long-term storage (>30 days): Store at -20°C in a sealed, desiccated container protected from light. Under these conditions, Bronchogen is expected to remain stable for 24 months or longer.
• Short-term storage (up to 30 days): Storage at 2-8°C (standard laboratory refrigerator) is acceptable, provided the vial remains sealed and protected from humidity.
• Transit / room temperature: Bronchogen tolerates ambient temperatures during shipping for up to 7-14 days without significant degradation, owing to its lyophilized state and small molecular size.

Reconstituted Solution Storage:

• Once reconstituted in bacteriostatic or sterile water, store at 2-8°C. Use within 14-21 days for solutions in bacteriostatic water; within 5-7 days for solutions in plain sterile water (no preservative).
• For longer-term storage of reconstituted material, aliquot into single-use volumes and freeze at -20°C or -80°C. Single freeze-thaw cycles are generally well tolerated; minimise repeated cycles to maintain potency.
• Always inspect reconstituted solution before use. Discard if cloudy, discoloured, or showing visible particulates.

Stability Notes:

• Bronchogen contains no cysteine residues, so disulfide scrambling is not a concern.
• The peptide contains no methionine, so methionine oxidation pathways are not applicable.
• Glutamic and aspartic acid residues can undergo slow deamidation or isomerisation in aqueous solution over extended periods; this is one reason to limit reconstituted shelf life.
• Protect from direct sunlight and prolonged UV exposure during all storage and handling steps.

Bronchogen is intended strictly for in vitro and laboratory research use. Storage practices should align with each institution's standard operating procedures for research-grade peptides.